Etoposide

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。

规格 价格 库存 购买数量  
RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NY[yOJdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX3TWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= MlL5NlU6PjB{OEK=
KellyCis83 M2rVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\oVodKSzVyPUCuNVbjiIoEsfMAjVAvODJizszN MYmyOVk3ODJ6Mh?=
SK-N-AS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjrTWM2OD1yLkK05qCKyrIkgJmwMlA{KM7:TR?= M2qzeVI2QTZyMkiy
SK-N-ASCis24 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP NUTqSlFNOjV7NkCyPFI>
U87 NWTtSXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLFRXAxNTVyIN88US=> MYq0PEBp NYDiT4RD\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDzbYxq[mmwaX6= M37OWVI2PzVyMkez
HCT116 M2nHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7jeIgzOC53LUKuOUDPxE1? NUHRfJh5PDkEoHlCpC=> NILOUIpKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= MlLWNlU4PDZ5NkO=
HT-29 NX3UXGV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TFUlAvPS1{LkWg{txO MVW0POKhcMLi Ml\HTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? MlPzNlU4PDZ5NkO=
Caco2 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPMS4FsOC53LUKuOUDPxE1? NIfhfVc1QMLiaNMg M1jabGlEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= NFLDWXQzPTd2Nke2Ny=>
COLO 205 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37oSlAvPS1{LkWg{txO NGDkV3Y1QMLiaNMg NWK0OnRKUUN3ME2xMlYyyqEEsdMgNE4xOsLizszN NYLHNoF1OjV5NE[3OlM>
SW480 NGHWOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XXdlAvPS1{LkWg{txO MUG0POKhcMLi MU\JR|UxRTRwOUNCpOKyyqByLkOzxsDPxE1? Moe4NlU4PDZ5NkO=
HEK293T NYHwTG1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq3NU02KM7:TR?= M3XufFQ5yqCqwrC= M2Cw[2lEPTB;Mj60NuKhyrIEoECuNFXDqM7:TR?= MV:yOVc1Pjd4Mx?=
Hep3B  NFjqT5pHfW6ldHnvckBCe3OjeR?= M1XqOFExKM7:TR?= Mnr0OFjDqGkEoB?= MWXy[YR2[2W|IITo[UBmdmijbnPpcoch\W[oZXP0JI9nKEKPUD22 MViyOVY{OzV4NB?=
Hep3B  MVzGeY5kfGmxbjDBd5NigQ>? Ml63NE4yNTFyIN88US=> MY[yOEBp M1TCbZN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YhcGWyY3nkbY4hdVKQQR?= M1T6UFI2PjN|NU[0
HEK293 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? NFnuZY0zPTZyM{GyNi=>
DU145 NWfuWnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HMWWlEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= M4L6VFI2PjB|MUKy
HCT15 M133WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\V[IFHUUN3ME2wMlgyyqEEsdMgNE4xOcLizszN MmnTNlU3ODNzMkK=
T47D MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L4fGlEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= NHL5dlEzPTZyM{GyNi=>
SMMC-7721 MV;GeY5kfGmxbjDBd5NigQ>? MmexOFAh|ryP M1rKbVQ5KGh? NXzPUGFrTE2VTx?= NVPYTYZ[cW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? NVLSSWtiOjV3NESzOlE>
MDA-MB-231 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDzfGw4OsLiaB?= M4jEdmlEPTB;MkGuNuKhyrIEoESuNuKh|ryP MXeyOVQ5PjJzOR?=
MCF-7 NVXnXmpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfBdm9OPzMEoHi= M3XEO2lEPTB;MUCuPeKhyrIEoEKuNeKh|ryP MkTMNlU1QDZ{MUm=
Jurkat Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPBRXQ4OsLiaB?= MnPWTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? NVqySXVwOjV2OE[yNVk>
HeLa NVH2NHRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[3NuKhcA>? M3HIWGlEPTB;Mz65xsDDucLiMj6zxsDPxE1? NYDRdY8yOjV2OE[yNVk>
MCF7  M{LIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uxSlUuOTByIN88US=> M2m4b|ch\A>? MXrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHnjbXYzPTR5Mk[xPS=>
K562 M3qxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDRO|LDqGh? M4PVRWlEPTB;MD6yPeKh|ryP MoXnNlUzQDJ4NUO=
K/VP.5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrzSlZEPzMEoHi= NXT1[JAzUUN3ME20MlnDqM7:TR?= MXGyOVI5OjZ3Mx?=
SH-EP  MX\GeY5kfGmxbjDBd5NigQ>? NXjHUYJTOjEEoN88[{9udA>? Mn7rNlTDqGh? MXjpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS MlqwNlUzPjF7OEG=
SCC25 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXXWpFDOjUEoHi= MWLJR|UxRTR|LkRCpOKyyqBzLkGyxsDPxE1? NUL5ZWw5OjV{MkC3Nlk>
CAL27 NH7yb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\6[FEzPMLiaB?= NWTG[JNlUUN3ME21Nk4yyqEEsdMgNU4xQcLizszN NHPOVWUzPTJ{MEeyPS=>
FaDu MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOyOOKhcA>? NF75R|BKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN NVTSbpJXOjV{MkC3Nlk>
SCC25 M17aUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO0POKhcA>? MULJR|UxRTJyLki2xsDDucLiMT6wO:Kh|ryP MV:yOVIzODd{OR?=
CAL27 M4XacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrNNnk1QMLiaB?= NEezWXdKSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN M3G2XVI2OjJyN{K5
FaDu NY\EZo03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfUOFjDqGh? M2npT2lEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= MVyyOVIzODd{OR?=
SCC25 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH70Wow4OsLiaB?= MkTTTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP NUToR4c5OjV{MkC3Nlk>
CAL27 NEDNWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M324UFczyqCq M{ftc2lEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= MVeyOVIzODd{OR?=
FaDu NXfr[5Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVy3NuKhcA>? MVHJR|UxRTVwMENCpOKyyqBzLkG1xsDPxE1? Ml3CNlUzOjB5Mkm=
MCF-7 NVPFVGhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i1U|Q5yqCqwrC= MXzEUXNQ MWLJR|UxRTdwMtMgxtHDqDBwONMg{txO NYDhfmROOjV{MU[zO|g>
T-47D MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO0POKhcMLi M4fVUGROW09? M2TVe2lEPTB;Nz63xsDDucLiMD63xsDPxE1? NHTvd4szPTJzNkO3PC=>
MDA-MB-231 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX71eFllPDkEoHlCpC=> M1;zeGROW09? MXvJR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? M3K4TlI2OjF4M{e4
DU145 M3nveWFxd3C2b4Ppd{BCe3OjeR?= MkXJNVAuOTByIN88US=> NIHBXIk5KGh? MYHEUXNQ NX61b5ZFcW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u Mlf5NlUyPDl4OEG=
DU145 stem-like M1LHbWFxd3C2b4Ppd{BCe3OjeR?= M3HxXlExNTFyMDFOwG0> MlfpPEBp NWHqeXkzTE2VTx?= MXXpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4my[|I2OTR7Nkix
DU145 MnzjSpVv[3Srb36gRZN{[Xl? NV;DTGVYOTBvMUCwJO69VQ>? MWiyJIg> MlLzSG1UVw>? NXjvO3RocW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2SwTVI2OTR7Nkix
DU145 stem-like M{Ljc2Z2dmO2aX;uJGF{e2G7 NGXSZY0yOC1zMECg{txO M37UN|IhcA>? MlKzSG1UVw>? M3zVZYlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1jsZlI2OTR7Nkix
UW228-3 NWjIWZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYewMlAyNTNyMDFOwG0> M3zZSVQ5KGh? M4nvZmROW09? M1X0OmlEPTB;MD65PeKh|ryP MX[yOVEyQTF6NR?=
NSCs NHy3WXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGwMlAyNTNyMDFOwG0> M4G4TFQ5KGh? NYXWOpk5TE2VTx?= M3;SemlEPTB;MD6zMVPDqM7:TR?= MnLYNlUyOTlzOEW=
MKL-1  M{PZc2Z2dmO2aX;uJGF{e2G7 NXf3d5J6OTBvMUCwNEBvVQ>? MnrtOEBl NGHhdVRqdmS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gUWhENUliZYjwdoV{e2mxbh?= MVOyOVEyPjd3NB?=
MCF7 EV MXnGeY5kfGmxbjDBd5NigQ>? NInQVm4yOC1zMECg{txO M4nPe|LjiImq MnT5bY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> M1\lVVI2ODh6MkCz
MCF 7BMI1 NITEenBHfW6ldHnvckBCe3OjeR?= Mn;wNVAuOTByIN88US=> MnzINwKBkWh? NFnLUIhqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? M{HrXVI2ODh6MkCz
MCF7 EV NHyxPFlHfW6ldHnvckBCe3OjeR?= M4XZdFExNTFyMDFOwG0> MYWy5qCKcA>? NW\sPYFoTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v M3H2V|I2ODh6MkCz
MCF7 BMI1 NX;JfXJyTnWwY4Tpc44hSXO|YYm= M2TMNFExNTFyMDFOwG0> NYXXWZVIOuLCiXi= NXTkO4VuTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v MYCyOVA5QDJyMx?=
HepG2 M3H4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v4bWROW00EoB?= Mn\jTWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= M{W3cVI2ODd6M{Gx
MOLT-3 NV7rXId5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPDd5VFVVORwrC= NYi1PVg6UUN3ME2wMlA2OcLiwsJCpFAvODB{wrFOwG0> NFOy[FQzPTB5OEOxNS=>
HT1080 NXL4c|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfMNYkyNTFyMDFOwG0> NUG4WYVpPC9{ND:0PEBp M1rI[2ROW00EoB?= M4nydIlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= MYGyOVA4QDB4NB?=
HT1080 M4TvOmZ2dmO2aX;uJGF{e2G7 MVOwMlAxODFvMUCwJO69VQ>? Ml;VNU0zPCCq NH\1VI5FVVORwrC= NGfxNlNqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NH;tTIkzPTB5OEC2OC=>
HT1080 NVrXPYp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTrNE4xODBzLUGwNEDPxE1? M3fK[FI1KGh? NFfsPJRFVVORwrC= M1WyZoNifXOnczDhckBqdmO{ZXHz[UBqdiC2aHWgcpVu[mW{IH;mJINmdGy|IHnuJGczN01uIIfobYxmKGSnY4LlZZNqdmdiUzDhcoQhTzFicHjhd4Uh[2WubIO= NEW5co8zPTB5OEC2OC=>
HD-MY-Z Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW3TGJCOjRxNEivO|IhcA>? MYrJR|Ux97zgMUCwJO69VQ>? MmHhNlUxPDh{M{[=
DOHH-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:5NlQhcA>? NWHxZlZmUUN3MP-8olExOCEQvF2= NI\6ToMzPTB2OEKzOi=>
DOHH-2 NGPsR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjWOFghcA>? MYfJR|UxRTF7LkpCpO69VQ>? M1\wWFI2ODR6MkO2
DOHH-2 M2H3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW3NkBp M1ryR2lEPTB;NdMg{txO MmXVNlUxPDh{M{[=
REH NGrPc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP2WY9nOjRiaB?= Ml;rTWM2OD1yLkCyO:Kh|ryP NHvt[HQzPTB2OEKzOi=>
REH NHK2NYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYi0PEBp NXLuSXY1UUN3ME2wMlAyPMLizszN M{\hSlI2ODR6MkO2
REH M3HtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3rXZc4OiCq MmPpTWM2OD1yLkCxOeKh|ryP MX6yOVA1QDJ|Nh?=
HH M1\oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zy[FI1KGh? NHTDW5dKSzVyPUGwOE44yqEQvF2= NFmzfVkzPTB2OEKzOi=>
HH MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvrO5R2PDhiaB?= NXjMOnRVUUN3ME20PE43yqEQvF2= NEXJVFQzPTB2OEKzOi=>
HH NWGyR3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLobYc{PzJiaB?= NFHWZ3VKSzVyPUG0MlfDqM7:TR?= NHXGUZYzPTB2OEKzOi=>
HuT-78 M3XGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX5d3IzPCCq NGLzUFNKSzVyPUmuN:Kh|ryP MX2yOVA1QDJ|Nh?=
HuT-78 NGnscHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvHPGhFPDhiaB?= NVvze4tFUUN3ME20MlPDqM7:TR?= NY\ZeIJPOjVyNEiyN|Y>
HuT-78 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXJdWs4PzJiaB?= NWnMUHFnUUN3ME20MlLDqM7:TR?= M2nDXlI2ODR6MkO2
OPM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[yOEBp MVLJR|UxRTJ2LkJCpO69VQ>? M3n0dFI2ODR6MkO2
OPM-2 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\kRVQ5KGh? Ml\sTWM2OD12wrFOwG0> MoHRNlUxPDh{M{[=
OPM-2 M1r3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLQUpA4OiCq M1[zeWlEPTB;MT6zxsDPxE1? Ml\ONlUxPDh{M{[=
RPMI-8226 NFfDRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2exS|I1KGh? NYDR[FZQUUN3ME2xNFYvPsLizszN M3KwfVI2ODR6MkO2
RPMI-8226 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUO0PEBp NHu3S|FKSzVyPUmxMlHDqM7:TR?= NWjBOJJXOjVyNEiyN|Y>
RPMI-8226 M2qwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW5O|IhcA>? MXLJR|UxRTF2LkpCpO69VQ>? M{\tVlI2ODR6MkO2
U-266 NX7MR3pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf1NlQhcA>? M1LFXmlEPTB;OE[uNuKh|ryP NVu1No1jOjVyNEiyN|Y>
U-266 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHnOFghcA>? MU\JR|UxRTZ6LkVCpO69VQ>? NIf2cYMzPTB2OEKzOi=>
U-266 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfyRmI4OiCq Mn\kTWM2OD1{Nz60xsDPxE1? NFLwTFczPTB2OEKzOi=>
Kelly MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqwMVExKM7:TR?= M4PCelczyqCq M{nqVWlEPTB;MT61NVjDqM7:TR?= MV2yOVAxQDlyMB?=
SH-SY5Y  NIf4[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j6eFAuOTBizszN MonFO|LDqGh? MlvKTWM2OD1yLke1OOKh|ryPwrC= MYeyOVAxQDlyMB?=
SK-N-AS M1zqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTPUG9JOC1zMDFOwG0> MUO3NuKhcA>? NV:3UFdoUUN3ME2xMlcyOsLizszNxsA> MkXkNlUxODh7MEC=
SK-N-DZ NEPpenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCwMVExKM7:TR?= MWm3NuKhcA>? NF\QUHhKSzVyPUWuOFg2yqEQvF2= NYnQS2k{OjVyMEi5NFA>
HepG2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LiRVQ5yqCq MUHEUXNQyqB? NWD4N4JOUUN3ME2xN{43PcLiwsJCpFAvQTMEoN88US=> NX;sb2lkOjR7OU[xN|Y>
A549 NGjDXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVW0POKhcA>? NXP4blRSTE2VT9Mg NFnB[oZKSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> MlHYNlQ6QTZzM{[=
MCF7 NFTveopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7LOFjDqGh? MWHEUXNQyqB? MYXJR|UxRThzLkC5xsDDucLiMUSuNlHDqM7:TR?= NGnreZczPDl7NkGzOi=>
HL-60  NYPRTWFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUS3NuKhcA>? M3r3PWlEPTB;MD6xNwKBjc7:TR?= Mn\DNlQ6QTNyMUS=
HL-60[R] MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr6R4c5PzMEoHi= NHXSVWFKSzVyPUOuNVLjiIYQvF2= NYnmN4U1OjR7OUOwNVQ>
MIAPACA MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7hUZpIUTVyPUGuN{DDuSByLkCzJO69VQ>? NYfhTZpOOjR7NUO4NlE>
MCF-7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfHRZZET0l3ME2wMlI2KMLzIECuNUDPxE1? NGjvZoozPDl3M{iyNS=>
HeLa NI\IV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L2[GdKPTB;MD62OEDDuSByLkSg{txO NEjyPGczPDl3M{iyNS=>
MO59K  MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7GcIFHPyCm NGTKTIdKSzVyPUCuNVfjiIYQvF2= NVT2fIxLOjR7NUO1OlE>
MO59J M1zRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\UU3o4KGR? NHHEbXpKSzVyPUCuNgKBjc7:TR?= MkPxNlQ6PTN3NkG=
ME 180 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK5OFjDqGkEoB?= NHT1dI9KSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= MnS2NlQ6PTNyMke=
MCF-7 NGTGO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYm0POKhcMLi NULvTFlkUUN3ME2yN{46KMLzIECuN-KBjc7:TR?= MW[yOFk2OzB{Nx?=
HeLa NVvwbmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:0POKhcMLi MoPvTWM2OD12LkexJOKyKDFwNPMAie69VQ>? NETPR5IzPDl3M{CyOy=>
MDA-MB-453 NInnem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLJe5l3PDkEoHlCpC=> NY\UW20yUUN3ME2xNk42KMLzIECuPFXjiIYQvF2= M3TXRlI1QTV|MEK3
MDA-MB-231 NVOxUWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfCOFjDqGkEoB?= NI[3UJlKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= MWKyOFk2OzB{Nx?=
PC-3 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnKOFjDqGkEoB?= NUW0VpNuUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= MlPvNlQ6PTNyMke=
HT-29 M4LKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLLPWI1QMLiaNMg MV3JR|UxRTJzLkS1JOKyKDNwOEhihKXPxE1? MWCyOFk2OzB{Nx?=
BGC-823 NY\1cZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO0POKhcMLi Ml63TWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP M4fEZ|I1Pzl|OEe3
HeLa Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7Fc2NzPDkEoHlCpC=> MXLJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= MY[yOFc6Ozh5Nx?=
A549 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVW0POKhcMLi NF7C[JdKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN M4nNW|I1Pzl|OEe3
HK-2 NFLwO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG0POKhcMLi Mmn0TWM2OD17LkG3JOKyKDFwNUlihKXPxE1? NXSzOXIxOjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
+ 展开

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
+ 展开
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Formulation: 生理盐水
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
稳定性 powder
in solvent
别名 VP-16, VP-16213

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID